Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of LDK378 in ALK-positive non-small cell lung cancer after chemotherapy and crizotinib
NL-OMON41391Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceritinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Jan 2013; status: active, not recruiting.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON41391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41391.